The DOI matches its Crossref record; 255 of the 256 references it cites were found in a registry or an index.
Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives
Abstract
From the 1960s to the early 2000s, alkylating agents (e.g., melphalan, cyclophosphamide, and bendamustine) remained a key component of standard therapy for newly-diagnosed or relapsed/refractory multiple myeloma (MM). Later on, their associated toxicities (including second primary malignancies) and the unprecedented efficacy of novel therapies have led clinicians to increasingly consider alkylator-free approaches. Meanwhile, new alkylating agents (e.g., melflufen) and new applications of old alkylators (e.g., lymphodepletion before chimeric antigen receptor T-cell [CAR-T] therapy) have emerged in recent years. Given the expanding use of antigen-directed modalities (e.g., monoclonal antibodies, bispecific antibodies, and CAR-T therapy), this review explores the current and future role of alkylating agents in different treatment settings (e.g., induction, consolidation, stem cell mobilization, pre-transplant conditioning, salvage, bridging, and lymphodepleting chemotherapy) to ellucidate the role of alkylator-based regimens in modern-day MM management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Over the past few decades, several non-targeted drugs have been approved for the treatment of multiple myeloma, including alkylating agents [40], corticosteroids [41–43], immunomodulatory imide drugs (IMiDs) [44–47], proteasome inhibitors (PIs) [42, 48–51], histone deacetylases (iHDACs) inhibitors [37, 52, 53], and XPO1 inhibitor [54–56] (Table 1).”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [40]
Citations
Cites
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269
Kumar, S. K., Rajkumar, S. V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,261
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Diagnosis and Management of Multiple Myeloma
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L., Tuazon, S. A., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,082
Cyclophosphamide and cancer: golden anniversary
Emadi, A., Jones, R. J., & Brodsky, R. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.146 · Cited by 1,058
Research works printed but not linked: 1
- Durie, 2020, Cancer J., 10, 53
Cited by
Sorted by citations
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Romagnani, P., Tang, S. C. W., Weins, A., Huber, T. B., Osafo, C., & Anders, H. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00671-w · Cited by 27
Role of Immune Cells and Immunotherapy in Multiple Myeloma
Radhakrishnan, V., Golla, U., & Kudva, A. K. (2024) · Life · doi:10.3390/life14040461 · Cited by 18
Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy
Özgencil, F., Gunindi, H. B., & Eren, G. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107509 · Cited by 15
CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review
Sadek, N. L., Costa, B. A., Nath, K., & Mailankody, S. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3057 · Cited by 13
Self-citationBanchi, M., Cox, M. C., & Bocci, G. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216900 · Cited by 10
Hu, S., Xu, J., Cui, W., Jin, H.-R., Wang, X., & Maimaitiyiming, Y. (2025) · Biomolecules · doi:10.3390/biom15050702 · Cited by 10
Talarico, M., Barbato, S., Maisnar, V., Delimpasi, S., Puppi, M., Rizzello, I., Pantani, L., Tacchetti, P., Martello, M., Vigliotta, I., et al. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06326-3 · Cited by 4
Li, Q., Ma, C., Zuo, L., Xu, A., Zhang, B., Zhao, F., Liu, L., Zhao, X., Hu, Y., & Sun, C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07065-2 · Cited by 2
Azadbeigi, P., Moosavinejad, N., & Rassouli, F. B. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s546061 · Cited by 1
Research Progress on Anti-tumor Mechanism of Artesunate Combined Drugs
Shi, M., & Yang, X. (2024) · Academic Journal of Science and Technology · doi:10.54097/jhbxr864 · Cited by 1
Cracchiolo, M. J., Davis, L. E., Matiatos, A. P., Davini, D. W., Husnain, M., Simpson, R. J., Voudouris, V., & Katsanis, E. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04688-y · Cited by 1
Melphalan improves toxicity of arsenic trioxide in adult T-cell leukemia/lymphoma cells
Khodadadi, F., Sadeghian, M. H., Delbari, Z., Kazemi, M., Koohpaykar, H., & Rassouli, F. B. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102109 · Cited by 1
Wagner, C. B., Julian, K. L., Bryan, B., Steinbach, M. N., Shewan, S., Maxwell, L., Vigil, M., Mohyuddin, G. R., Godara, A., McClune, B. L., et al. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2350670
Anticancer Drug Utilization and Prescription Practices in a Saudi Cancer Center (2014-2022)
Badheeb, A. M., Munjem, M. F. A., Ahmed, F., Aljedaani, H., Assiri, N., Abdulaziz, A., Abubakar, A., AlQurayshah, M., & Badheeb, M. A. (2025) · F1000Research · doi:10.12688/f1000research.147910.2
Hu, C., Chen, W., Zhang, P., Shen, T., & Zhao, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1696768
Tian, Y., Su, L., Li, Y., Ye, M., Zhang, Y., Li, Q. Q., Jiao, Y., & Wu, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1770120
Periplocin targets STAT3 to suppress MYC expression and inhibit multiple myeloma cell proliferation
Wei, R.-F., Chen, J., Lai, S.-P., Chen, Z.-A., Zhou, Y.-Y., Liao, Y.-P., & Chen, Y. (2026) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2026.07.002
Akrawi, D., Datta, S., Hatipoğlu, S., Wechalekar, A. D., Ghose, A., Alkhateeb, A., Walker, J. M., & Ghosh, A. K. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02397-x
Metadata
- Authors
- Costa, B. A., Mouhieddine, T. H., Ortiz, R. J., & Richter, J.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Tisch Cancer Institute (US)
- Corresponding author
- Richter, Joshua
- Venue
- Critical Reviews in Oncology/Hematology
- Publisher
- Elsevier BV
- Published
- 2023-07
- Volume
- 187
- Pages
- 104040
- ISSN
- 1040-8428 (ISSN-L)
- OpenAlex
- W4378212210
- Cited by
- 18
- References
- 256
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 6 · 2023: 1
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Critical Reviews in Oncology/Hematology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- alkylating agents, multiple myeloma, melphalan, cyclophosphamide, bendamustine, melflufen, lymphocyte depletion, CAR T-cell therapy, second primary malignancy, relapsed/refractory multiple myeloma, stem cell mobilization, pre-transplant conditioning, consolidation therapy, bridging therapy
- MeSH terms
- Bendamustine Hydrochloride, Receptors, Chimeric Antigen, Alkylating Agents, Cyclophosphamide, Humans, Multiple Myeloma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
